Table 1. Patient and treatment characteristics.
| Characteristics | Number | Percentage |
|---|---|---|
| Patient characteristic | ||
| Age mean (year) | 49 | |
| range | 12–80 | |
| Gender male | 644 | 74.1% |
| female | 225 | 25.9% |
| Pathology | ||
| WHO I | 1 | 0.1% |
| WHO II-III | 868 | 99.9% |
| T T1 | 209 | 24.1% |
| T2 | 317 | 36.5% |
| T3 | 224 | 25.8% |
| T4 | 119 | 13.7% |
| N N0 | 191 | 22.0% |
| N1 | 319 | 36.7% |
| N2 | 250 | 28.8% |
| N3 | 109 | 12.5% |
| Stage I | 51 | 5.9% |
| II | 265 | 30.5% |
| III | 331 | 38.1% |
| IVA | 113 | 13.0% |
| IVB | 109 | 12.5% |
| Diagnositc imaging technique | ||
| MRI | 869 | 100% |
| Surgery before radiotherapy | ||
| Nodal excision | 46 | 5.3% |
| Radiotherapy | ||
| Total prescription dose(Gy) (mean+/−SD) | ||
| primary tumor | 68.26+/−3.51 | |
| metastatic lymph nodes | 66.37+/−1.37 | |
| Additional boost | ||
| Nasopharyngeal boost | 51 | 5.9% |
| Nodal boost | 72 | 8.3% |
| Unplanned break during radiotherapy > 3 days | 61 | 7.0% |
| Completion of radiation | 869 | 100% |
| Chemotherapy | 737 | 84.8% |
| Chemotherapy strategy | ||
| Induction plus concurrent chemotherapy | 297 | 34.2% |
| Induction plus adjuvant chemotherapy | 246 | 28.3% |
| Induction plus radiation alone | 101 | 11.6% |
| Concurrent with/without adjuvant chemotherapy | 93 | 10.7% |
| Total dose of cisplatin (mg/m2) (mean+/−SD) | 231.9+/−132.1 |